• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

CHZ868 Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5764319

MBS5764319 is an inhibitor targeting CHZ868. CHZ868 is a type II JAK2 inhibitor (IC50: 0.17 uM in EPOR JAK2 WT Ba/F3 cell). More details

Please Inquire
Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
CHZ868, Inhibitor
Full Product Name
CHZ868
Product Gene Name
CHZ868, inhibitor
Form/Format
Solid. Powder
Purity/Purification
98.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
423.42
Solubility
DMSO: 145mg/mL (342.45mM)
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
C22H19F2N5O2
SMILES
CC(NC1=CC(OC2=CC=C(N(C)C(NC3=CC=C(F)C=C3F)=N4)C4=C2C)=CC=N1)=O
CAS Number
1895895-38-1
Cell Research
CHZ868 is dissolved in DMSO to make 10mM stock solution and diluted in culture media. Cells are treated with CHZ868 (0, 0.05, 0.1, 0.2uM) or vehicle (DMSO). After 48 hr (Ba/F3 cells) or 72 hr (MHH-CALL4 and PDX cells), CellTiter-Glo Luminescent Cell Viability Assay is added (10uL undiluted or 25 uL of a 1:2 dilution in each well) and plates are read [2].
In Vitro
CHZ868 is characterized by good metabolic stability, and low water solubility, as well as by moderate blood clearance and good oral bioavailability. CHZ868 improves survival in mice with human or murine B-ALL. CHZ868 and dexamethasone synergistically induce apoptosis in JAK2-dependent B-ALLs and further improves survival compared to CHZ868 alone [2].

Product Categories/Family for CHZ868, inhibitor

Angiogenesis; JAK; Chromatin/Epigenetic; JAK/STAT signaling; Stem Cells

Product References and Citations for CHZ868, inhibitor

Meyer SC, et al. CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. Cancer Cell. 2015 Jul 13;28(1):15-28.
Meyer SC, et al. CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. Cancer Cell. 2015 Jul 13;28(1):15-28.
Wu SC, et al. Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2015 Jul 13;28(1):29-41.
Wu SC, et al. Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2015 Jul 13;28(1):29-41.

Other Notes

Small volumes of CHZ868, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000